News & Updates
Filter by Specialty:
Novel PPARγ modulator shows therapeutic potential in acne vulgaris
In the treatment of patients with acne vulgaris, the investigational peroxisome proliferator-activated receptor-γ (PPARγ) modulator N-acetyl-GED-0507-34-LEVO (NAC-GED) 5% gel appears to help clear lesions and improve acne severity while being safe, according to the results of a phase IIb study.
Novel PPARγ modulator shows therapeutic potential in acne vulgaris
01 Jul 2022
Ibrutinib-bendamustine-rituximab combo promising for older patients with mantle-cell lymphoma
A treatment combination comprising the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib plus bendamustine and rituximab, followed by rituximab maintenance therapy, improved progression-free survival (PFS) in older patients with untreated mantle-cell lymphoma, according to results of the SHINE* trial presented at ASCO 2022.
Ibrutinib-bendamustine-rituximab combo promising for older patients with mantle-cell lymphoma
30 Jun 2022
Persistent ALT elevation triples risk of future T2D among overweight, obese children
Children with overweight or obesity risk developing future type 2 diabetes (T2D) by threefold in the presence of persistent elevations in alanine aminotransferases (ALT), according to a study presented at the 54th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN 2022).
Persistent ALT elevation triples risk of future T2D among overweight, obese children
30 Jun 2022
Antioxidant cocktail works against diabetic polyneuropathy in T2D
Treatment with a combination of succinic acid, inosine, nicotinamide, and riboflavin (SINR) is safe and alleviates the symptoms of diabetic polyneuropathy in patients with type 2 diabetes (T2D), according to data from the CYLINDER study.
